目的探讨复方苦参注射液用于WHO三阶梯止痛原则中的止痛价值。方法随机选取医院2019年7月—2022年4月150例癌痛患者,按照随机数字表法分为治疗组75例,对照组75例。对照组轻度癌痛患者使用布洛芬缓释片,中度癌痛患者使用盐酸曲马多缓释...目的探讨复方苦参注射液用于WHO三阶梯止痛原则中的止痛价值。方法随机选取医院2019年7月—2022年4月150例癌痛患者,按照随机数字表法分为治疗组75例,对照组75例。对照组轻度癌痛患者使用布洛芬缓释片,中度癌痛患者使用盐酸曲马多缓释片联合布洛芬缓释片,重度癌痛患者使用盐酸吗啡缓释片联合布洛芬缓释片联合醋酸地塞米松片处理,治疗组在对照组基础上加用复方苦参注射液,21 d为1个疗程。观察比较两组治疗后的疼痛有效缓解率以及疼痛程度数字评估量表(numerical rating scale,NRS)、EORTC QLQ—C30(EuroPean organization for Research and Treatment)量表评分、匹兹堡睡眠质量指数与安全性。结果经治疗,治疗组有效缓解率升高(P<0.05);治疗组的NRS评分明显升高(P<0.01);EORTC QLQ—C30量表评分部分升高(P<0.05);匹兹堡睡眠质量指数明显升高(P<0.01);两组在治疗期间均出现不良反应,但治疗组不良事件发生率在恶心呕吐与便秘两方面更低(P<0.05);结果差异均有统计学意义(P<0.05)。结论在WHO三阶梯止痛原则基础上,加用复方苦参注射液可以明显提高止痛效果,明显改善生活质量,提高患者睡眠质量,同时也可降低不良事件发生情况,因此值得在临床推广应用。展开更多
For patients with esophageal carcinoma (ESCA), health-related quality of life (HRQoL) has now become an essential feature. To examine the quality of life of preoperative and postoperative ESCA patients, we used the Eu...For patients with esophageal carcinoma (ESCA), health-related quality of life (HRQoL) has now become an essential feature. To examine the quality of life of preoperative and postoperative ESCA patients, we used the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C-30) and the Quality of Life Questionnaire Oesophageal 18 (QLQ-OES18). Using the EORTC QLQ-C30 and the QLQ-OES18 questionnaire, the analysis of the quality of life scores of 246 patients with oesophageal cancer who were operated on at the Sun Yat-sen University Cancer Centre during the period 2013 to 2015 was carried out. Differences between pre- and post-surgical EORTC QLQ C-30 and QLQ-OES18 scores were examined using the Student’s t-test. Patients’ global health status (QoL) decreased significantly one month after the operation but gradually recovered within a year. In terms of the role function, the emotional function, the cognitive function, and the perception and function variants, EORTC QLQ-C30 and QLQ-OES18 scores increased statistically significantly, as did clinical signs variables such as exhaustion, nausea, vomiting, pain, sleeplessness, decreased appetite, stomach pain, and economic hardship. After surgery, there was an improvement in functional and symptom domains in esophageal carcinoma patients. EORTC QLQ-C30 and QLQ-OES18 can be used to assess the HRQoL before and after surgical procedures.展开更多
<strong>Background: </strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">Ovarian cancer accounts for 4% of can...<strong>Background: </strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">Ovarian cancer accounts for 4% of cancers occurring in women and ranks first in gynecological cancer mortality. Maintaining and improving quality of life is an important goal of cancer treatment. The toxicities of cancer treatment particularly chemotherapy can impact an individual’s wellbeing. </span><b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> Assessment of quality of life among ovarian cancer patients receiving chemotherapy.</span><b><span style="font-family:Verdana;"> Method: </span></b><span style="font-family:Verdana;">A descriptive study was conducted among 202 patients with ovarian cancer treated at the National Institute of Cancer Research and Hospital in Bangladesh. Ethical approval was received from the ethics committee of NICRH. Data was collected using the EORTC QLQC30 questionnaire and the ovarian cancer specific EORTC QOL OV-28 module. Functional, symptomatic and global variables were scored and analyzed by SPSS. Multiple linear regressions determined the effects of predictor variables and correlation of the global health status with other variables. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">48.6% </span><span style="font-family:Verdana;">of patients were ages 41 to 50 years. The mean score of global health status was</span><span style="font-family:Verdana;"> 55.77. Deteriorating emotional function, distressing physical and psychological symptoms, sexual dysfunction and financial difficulties adversely affect the quality of life. Their correlation with global health status was strongly significant (P value < 0.05). Fatigue (r value </span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.604;p < 0.05) loss of appetite (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.442;p < 0.05), insomnia (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.339;p < 0.05), dyspnea (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.377;p < 0.05), heartburn (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.369;p < 0.05), and alopecia (r value </span><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">0.262;p < 0.05) were negatively associated with QOL. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The overall quality of life among the ovarian cancer patients receiving chemotherapy is low. Increasing knowledge in this area will help clinicians to optimize patient management. Interventions should focus on both physical and psychological and sexual health issues that adversely affect the quality of life</span></span></span></span></span><span style="font-family:Verdana;">.</span>展开更多
文摘目的探讨复方苦参注射液用于WHO三阶梯止痛原则中的止痛价值。方法随机选取医院2019年7月—2022年4月150例癌痛患者,按照随机数字表法分为治疗组75例,对照组75例。对照组轻度癌痛患者使用布洛芬缓释片,中度癌痛患者使用盐酸曲马多缓释片联合布洛芬缓释片,重度癌痛患者使用盐酸吗啡缓释片联合布洛芬缓释片联合醋酸地塞米松片处理,治疗组在对照组基础上加用复方苦参注射液,21 d为1个疗程。观察比较两组治疗后的疼痛有效缓解率以及疼痛程度数字评估量表(numerical rating scale,NRS)、EORTC QLQ—C30(EuroPean organization for Research and Treatment)量表评分、匹兹堡睡眠质量指数与安全性。结果经治疗,治疗组有效缓解率升高(P<0.05);治疗组的NRS评分明显升高(P<0.01);EORTC QLQ—C30量表评分部分升高(P<0.05);匹兹堡睡眠质量指数明显升高(P<0.01);两组在治疗期间均出现不良反应,但治疗组不良事件发生率在恶心呕吐与便秘两方面更低(P<0.05);结果差异均有统计学意义(P<0.05)。结论在WHO三阶梯止痛原则基础上,加用复方苦参注射液可以明显提高止痛效果,明显改善生活质量,提高患者睡眠质量,同时也可降低不良事件发生情况,因此值得在临床推广应用。
文摘For patients with esophageal carcinoma (ESCA), health-related quality of life (HRQoL) has now become an essential feature. To examine the quality of life of preoperative and postoperative ESCA patients, we used the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ C-30) and the Quality of Life Questionnaire Oesophageal 18 (QLQ-OES18). Using the EORTC QLQ-C30 and the QLQ-OES18 questionnaire, the analysis of the quality of life scores of 246 patients with oesophageal cancer who were operated on at the Sun Yat-sen University Cancer Centre during the period 2013 to 2015 was carried out. Differences between pre- and post-surgical EORTC QLQ C-30 and QLQ-OES18 scores were examined using the Student’s t-test. Patients’ global health status (QoL) decreased significantly one month after the operation but gradually recovered within a year. In terms of the role function, the emotional function, the cognitive function, and the perception and function variants, EORTC QLQ-C30 and QLQ-OES18 scores increased statistically significantly, as did clinical signs variables such as exhaustion, nausea, vomiting, pain, sleeplessness, decreased appetite, stomach pain, and economic hardship. After surgery, there was an improvement in functional and symptom domains in esophageal carcinoma patients. EORTC QLQ-C30 and QLQ-OES18 can be used to assess the HRQoL before and after surgical procedures.
文摘<strong>Background: </strong><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">Ovarian cancer accounts for 4% of cancers occurring in women and ranks first in gynecological cancer mortality. Maintaining and improving quality of life is an important goal of cancer treatment. The toxicities of cancer treatment particularly chemotherapy can impact an individual’s wellbeing. </span><b><span style="font-family:Verdana;">Objective:</span></b><span style="font-family:Verdana;"> Assessment of quality of life among ovarian cancer patients receiving chemotherapy.</span><b><span style="font-family:Verdana;"> Method: </span></b><span style="font-family:Verdana;">A descriptive study was conducted among 202 patients with ovarian cancer treated at the National Institute of Cancer Research and Hospital in Bangladesh. Ethical approval was received from the ethics committee of NICRH. Data was collected using the EORTC QLQC30 questionnaire and the ovarian cancer specific EORTC QOL OV-28 module. Functional, symptomatic and global variables were scored and analyzed by SPSS. Multiple linear regressions determined the effects of predictor variables and correlation of the global health status with other variables. </span><b><span style="font-family:Verdana;">Results: </span></b><span style="font-family:Verdana;">48.6% </span><span style="font-family:Verdana;">of patients were ages 41 to 50 years. The mean score of global health status was</span><span style="font-family:Verdana;"> 55.77. Deteriorating emotional function, distressing physical and psychological symptoms, sexual dysfunction and financial difficulties adversely affect the quality of life. Their correlation with global health status was strongly significant (P value < 0.05). Fatigue (r value </span></span></span></span><span><span><span style="font-family:;" "=""><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.604;p < 0.05) loss of appetite (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.442;p < 0.05), insomnia (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.339;p < 0.05), dyspnea (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.377;p < 0.05), heartburn (r value </span><span style="font-family:Verdana;">-</span><span style="font-family:Verdana;">0.369;p < 0.05), and alopecia (r value </span><span style="font-family:Verdana;">-</span><span><span style="font-family:Verdana;">0.262;p < 0.05) were negatively associated with QOL. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The overall quality of life among the ovarian cancer patients receiving chemotherapy is low. Increasing knowledge in this area will help clinicians to optimize patient management. Interventions should focus on both physical and psychological and sexual health issues that adversely affect the quality of life</span></span></span></span></span><span style="font-family:Verdana;">.</span>
